Jeffrey Madison had been accused of participation in a scheme to pay kickbacks to physicians for testing referrals and billing healthcare programs for the tests.
The BARDA funding will support studies to validate the Melbourne, Australia-headquartered firm's flagship FebriDx rapid host-response respiratory infection test in low complexity settings and ...